Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Vicore Pharma Holding AB ( (SE:VICO) ) just unveiled an announcement.
Vicore Pharma is a Swedish clinical-stage biopharmaceutical company developing angiotensin II type 2 receptor agonists for respiratory and fibrotic diseases, led by buloxibutid for idiopathic pulmonary fibrosis, which has secured Orphan Drug and Fast Track designations in the US. It is currently listed on Nasdaq Stockholm and is building a stronger foothold in the US market as its key IPF program progresses through a pivotal mid-stage trial.
The company has filed a registration statement with the US Securities and Exchange Commission and applied to list American Depositary Receipts on Nasdaq US, aiming for a dual listing without issuing new shares or raising capital. Management says a US listing should broaden access to American investors and support its late-stage buloxibutid program and wider ambitions in pulmonary and fibrotic disease, with the move underlining confidence in its cash position and upcoming Phase 2b ASPIRE data in mid-2027.
The dual listing remains contingent on the effectiveness of the registration statement and approval of the listing application, and Vicore will not receive proceeds from the ADR listing itself. If successful, the step could enhance the company’s visibility and liquidity in the world’s largest biotech capital market, potentially strengthening its strategic position ahead of key clinical milestones in idiopathic pulmonary fibrosis and related indications.
The most recent analyst rating on (SE:VICO) stock is a Buy with a SEK38.00 price target. To see the full list of analyst forecasts on Vicore Pharma Holding AB stock, see the SE:VICO Stock Forecast page.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company focused on developing angiotensin II type 2 receptor agonists as disease-modifying therapies for respiratory and fibrotic conditions, including idiopathic pulmonary fibrosis. Its lead oral small molecule, buloxibutid, holds Orphan Drug and Fast Track status from the US Food and Drug Administration and is being evaluated in the global 52-week Phase 2b ASPIRE trial in idiopathic pulmonary fibrosis.
The company is listed on Nasdaq Stockholm under the ticker VICO and is expanding its presence in the United States as its pipeline advances. Vicore aims to leverage its novel mechanism of action across a broader range of pulmonary and fibrotic diseases, positioning itself within a specialized niche of the biotech sector focused on severe, underserved lung disorders.
Average Trading Volume: 550,602
Technical Sentiment Signal: Hold
Current Market Cap: SEK3.1B
See more data about VICO stock on TipRanks’ Stock Analysis page.